The therapies developed against these studied cytokines—IL-1β, IL-6, and TNF-α—can represent alternatives to current chemotherapeutic and immunological treatments, considering the toxicity and lack of effectiveness of chemotherapy in colorectal cancer. This evidence concerns the gene IL1B and colorectal cancer.